Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
February 04, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate in three upcoming...
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
January 29, 2020 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented preclinical results of...
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
January 24, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tonix Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia Lack of a Food Effect for TNX-102 SL Supports...
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
January 23, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be...
Tonix Pharmaceuticals to Present at Biotech Showcase 2020
January 07, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
December 16, 2019 15:15 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed as an Immediate Release Three-Times-a-Day Antidepressant in Europe, Asia, Russia and Latin America First Efficacy Trial Planned...
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
December 11, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European...
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
December 10, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Tonix...
Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event
December 04, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro...
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
December 03, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained...